Goodwin Procter advised Cerevel Therapeutics on the deal.Cerevel Therapeutics (Nasdaq: CERE) announced its underwritten public offering of 14,000,000 shares of common stock at a public offering price…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
